{"id":"indacaterol-glycopyrronium","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Urinary retention"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Indacaterol activates beta-2 adrenergic receptors on bronchial smooth muscle, causing bronchodilation and improved airflow. Glycopyrronium blocks M3 muscarinic receptors, preventing acetylcholine-induced bronchoconstriction. Together, these complementary mechanisms provide dual bronchodilation for sustained airway opening in chronic obstructive pulmonary disease.","oneSentence":"Indacaterol is a long-acting beta-2 agonist that stimulates airway smooth muscle relaxation, while glycopyrronium is an anticholinergic that blocks muscarinic receptors to further dilate airways.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:39.759Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT05776927","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-29","conditions":"Asthma","enrollment":304},{"nctId":"NCT06035393","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":82},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT05274425","phase":"","title":"A 24-week rPMS Study in Real-world Setting for Enerzair","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-09","conditions":"Asthma","enrollment":600},{"nctId":"NCT06619210","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2022-01-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":102},{"nctId":"NCT06643078","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD","status":"RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2023-12-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":474},{"nctId":"NCT04656223","phase":"","title":"Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-17","conditions":"Asthma","enrollment":434},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT04259164","phase":"PHASE3","title":"Anti-inflammatory Effects Glycopyrronium","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2020-09-10","conditions":"Asthma, Allergic Asthma","enrollment":28},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT05288075","phase":"PHASE1","title":"Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2022-02-28","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT04011475","phase":"","title":"A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-12-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1617},{"nctId":"NCT05120986","phase":"","title":"An Observational Prospective Study to Characterize Patients Initiating Enerzair® Breezhaler®, With or Without Sensor, as a Maintenance Treatment for Asthma","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2022-02-15","conditions":"Asthma","enrollment":""},{"nctId":"NCT04206761","phase":"PHASE3","title":"Investigating the Effects of QVM149 on MRI Ventilation Defects","status":"WITHDRAWN","sponsor":"Dr. Grace Parraga","startDate":"2021-12-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT02579850","phase":"PHASE3","title":"2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1532},{"nctId":"NCT03158311","phase":"PHASE3","title":"Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-02-05","conditions":"Asthma","enrollment":1426},{"nctId":"NCT04856098","phase":"PHASE1","title":"Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2021-05-07","conditions":"Healthy Volunteers","enrollment":34},{"nctId":"NCT02872090","phase":"PHASE4","title":"Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT02634983","phase":"PHASE4","title":"QVA Mechanistic Efficacy Study (Receptor Effects, Etc)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":31},{"nctId":"NCT03379233","phase":"PHASE3","title":"A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":7},{"nctId":"NCT04509661","phase":"PHASE4","title":"Efficacy and Safety of Inhaled Bronchodilator in Non-CF Bronchiectasis With Airflow Limitation","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2020-09-01","conditions":"Bronchiectasis Adult","enrollment":200},{"nctId":"NCT02571777","phase":"PHASE3","title":"Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-08","conditions":"Asthma","enrollment":3092},{"nctId":"NCT03100825","phase":"PHASE3","title":"A Long-term Safety Study of QVM149 in Japanese Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-04-28","conditions":"Asthma","enrollment":96},{"nctId":"NCT02566031","phase":"PHASE4","title":"A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-03-23","conditions":"COPD","enrollment":379},{"nctId":"NCT02202616","phase":"PHASE4","title":"Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":401},{"nctId":"NCT02567214","phase":"PHASE4","title":"Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-06","conditions":"COPD","enrollment":50},{"nctId":"NCT02603393","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-20","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1053},{"nctId":"NCT02516592","phase":"PHASE4","title":"Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-10-13","conditions":"COPD","enrollment":500},{"nctId":"NCT01985334","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02-14","conditions":"COPD","enrollment":4389},{"nctId":"NCT02442206","phase":"PHASE4","title":"Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05-18","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":62},{"nctId":"NCT02552160","phase":"","title":"DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3732},{"nctId":"NCT02233543","phase":"PHASE4","title":"A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":38},{"nctId":"NCT00570778","phase":"PHASE2","title":"Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":154},{"nctId":"NCT03364829","phase":"PHASE4","title":"Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program","status":"UNKNOWN","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2016-01-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT02487498","phase":"PHASE3","title":"Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":355},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02487446","phase":"PHASE3","title":"Efficacy and Safety Study of QVA149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":357},{"nctId":"NCT02576626","phase":"PHASE4","title":"Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD","status":"COMPLETED","sponsor":"Wouter H. van Geffen","startDate":"2015-12","conditions":"COPD","enrollment":40},{"nctId":"NCT02953041","phase":"PHASE4","title":"Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2016-10","conditions":"Asthma","enrollment":31},{"nctId":"NCT02125734","phase":"PHASE4","title":"Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":88},{"nctId":"NCT02693769","phase":"PHASE2, PHASE3","title":"A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils","status":"TERMINATED","sponsor":"Mundipharma Research Limited","startDate":"2016-07","conditions":"ACOS (Fixed Airflow Obstruction and Elevated Eosinophils)","enrollment":2},{"nctId":"NCT01610037","phase":"PHASE3","title":"Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1215},{"nctId":"NCT01782326","phase":"PHASE3","title":"QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":3362},{"nctId":"NCT01996319","phase":"PHASE3","title":"Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":194},{"nctId":"NCT01682863","phase":"PHASE3","title":"A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":614},{"nctId":"NCT01727141","phase":"PHASE3","title":"A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1042},{"nctId":"NCT01697696","phase":"PHASE3","title":"Long Term Safety Study of NVA237 vs QAB149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":511},{"nctId":"NCT01712516","phase":"PHASE3","title":"A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1001},{"nctId":"NCT01709903","phase":"PHASE3","title":"A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":744},{"nctId":"NCT01604278","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":449},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT01529632","phase":"PHASE3","title":"Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":193},{"nctId":"NCT01285492","phase":"PHASE3","title":"Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":160},{"nctId":"NCT01490125","phase":"PHASE3","title":"The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":247},{"nctId":"NCT01120691","phase":"PHASE3","title":"Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2224},{"nctId":"NCT01834885","phase":"PHASE3","title":"A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT01860066","phase":"PHASE3","title":"A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":""},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT01315249","phase":"PHASE3","title":"QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":523},{"nctId":"NCT01294787","phase":"PHASE3","title":"Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02","conditions":"COPD","enrollment":85},{"nctId":"NCT01120717","phase":"PHASE3","title":"A Study to Assess the Long-term Safety of QVA149","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":339},{"nctId":"NCT00558285","phase":"PHASE2","title":"Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":257}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"DRUG INTERACTION"},{"count":5,"reaction":"SARS-COV-2 SEPSIS"},{"count":4,"reaction":"TUBULOINTERSTITIAL NEPHRITIS"},{"count":2,"reaction":"ACUTE KIDNEY INJURY"},{"count":2,"reaction":"EPISTAXIS"},{"count":2,"reaction":"INTERNATIONAL NORMALISED RATIO INCREASED"},{"count":2,"reaction":"STERILE PYURIA"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"},{"count":1,"reaction":"CHOLESTATIC LIVER INJURY"},{"count":1,"reaction":"COVID-19 PNEUMONIA"}],"_approvalHistory":[],"publicationCount":142,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant A with charcoal","Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant B with charcoal","Indacaterol/glycopyrronium Easyhaler® 85/43 µg/dose, inhalation powder, product variant C with charcoal","Ultibro® Breezhaler® 85/43 µg inhalation powder, hard capsule with charcoal"],"phase":"marketed","status":"active","brandName":"Indacaterol/glycopyrronium","genericName":"Indacaterol/glycopyrronium","companyName":"Orion Corporation, Orion Pharma","companyId":"orion-corporation-orion-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Indacaterol is a long-acting beta-2 agonist that stimulates airway smooth muscle relaxation, while glycopyrronium is an anticholinergic that blocks muscarinic receptors to further dilate airways. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}